Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

David Robert Spigel, Craig H. Reynolds, David Michael Waterhouse et al. · Journal of Thoracic Oncology · 2018

Cited by 229 works. doi:10.1016/j.jtho.2018.02.022 Open-access PDF

Authors

References